

# Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry

H.-A. Kim<sup>1</sup>, E. Lee<sup>1</sup>, S.-K. Lee<sup>2</sup>, Y.-B. Park<sup>3</sup>, Y.N. Lee<sup>4</sup>, H.J. Kang<sup>4</sup>, K. Shin<sup>2</sup>

<sup>1</sup>Ajou University School of Medicine, Suwon, Republic of Korea; <sup>2</sup>Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea;

<sup>3</sup>Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea;

<sup>4</sup>Celltrion Healthcare Co. Ltd, Incheon, Republic of Korea.

---

## Abstract

### Objective

To evaluate the long-term drug retention, efficacy, and safety of the infliximab biosimilar CT-P13 in Korean patients with ankylosing spondylitis (AS) in clinical practice. The primary outcome was drug retention (i.e. time to treatment discontinuation or changing to another biologic) in Korean patients with AS. Additional outcomes included efficacy and safety.

---

### Methods

Data were collected through the Korean College of Rheumatology Biologics (KOBIO) registry (ClinicalTrials.gov identifier: NCT01965132). CT-P13 efficacy was assessed using standard disease activity parameters, and safety was evaluated by adverse events (AEs).

---

### Results

Between December 2012 and December 2017, 244 patients with AS treated with CT-P13 were enrolled. Of those, 203 (83.2%) received CT-P13 as first-line therapy. The median duration of treatment was 2.05 years. After 4 years' follow-up, the retention rate of CT-P13 in the overall patient population was 66%. Treatment changes or discontinuations occurred in 38 (15.6%) and 32 (13.1%) patients, respectively. Lack of efficacy was the most common reason for treatment changes, whereas AEs were the most common single cause of discontinuation. Disease activity decreased markedly from baseline following initiation of CT-P13 treatment, and thereafter remained stable. A total of 313 AEs occurred in 118 patients (48.4%); the majority (94.6%) were mild or moderate in severity. The most common treatment-related AEs were infusion or injection-site reactions (4.1% of patients), uveitis (3.7%), and skin rash (3.7%).

---

### Conclusion

In this real-world study, CT-P13 demonstrated encouraging drug retention rates and times, together with reasonable long-term efficacy and safety, in Korean patients with AS.

---

### Key words

ankylosing spondylitis, biosimilar pharmaceuticals, CT-P13, infliximab, registries

Hyoun-Ah Kim, MD, PhD  
 Eunyoung Lee, MS  
 Sun-Kyung Lee, PhD  
 Yong-Beom Park, MD, PhD  
 Young Nam Lee, PhD  
 Hee Jung Kang, MSc  
 Kichul Shin, MD, PhD

Please address correspondence to:  
 Dr Kichul Shin,  
 Seoul Metropolitan Government-Seoul  
 National University Boramae  
 Medical Center,  
 20 Boramae-ro-5-gil, Dongjak-gu,  
 07061 Seoul, Republic of Korea.  
 E-mail: kideb1@gmail.com

Received on December 18, 2018; accepted  
 in revised form on May 23, 2019.

© Copyright CLINICAL AND  
 EXPERIMENTAL RHEUMATOLOGY 2019.

## Introduction

Biosimilars have joined the list of biologic therapies and are used for the treatment of active rheumatic diseases (1). These are products that are highly similar to licensed biologic medicines or reference products (RPs) (2-4). CT-P13 is an immunoglobulin gamma 1 chimeric human–murine monoclonal antibody and is the first biosimilar monoclonal antibody to be approved by the European Medicines Agency (5-9). CT-P13 is approved in numerous countries for the same indications as infliximab RP, including ankylosing spondylitis (AS), rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis, and inflammatory bowel diseases (IBDs) (5, 10-13). In the PLANETAS study, a randomised, double-blind trial involving 250 patients with active AS, the pharmacokinetics, efficacy, and safety profile of CT-P13 were comparable with those of infliximab RP (6, 14). Furthermore, the PLANETAS open-label extension study showed that changing from infliximab RP to CT-P13 had no negative effects on either efficacy or safety (8). Similar findings were obtained in patients with active RA in the randomised, double-blind PLANETRA study and the PLANETRA open-label extension study (7, 9). A meta-analysis of 13 randomised controlled trials in patients with AS has confirmed that CT-P13 has comparable efficacy and safety to infliximab and other biologic agents (adalimumab, etanercept, and golimumab) (15).

To date, however, few studies have investigated the long-term efficacy or safety of CT-P13 in patients with AS. In the PLANETAS extension study, patients originally randomised to receive CT-P13 were maintained on treatment for an additional 48 weeks, making a total of 102 weeks of follow-up, while those originally randomised to infliximab RP received CT-P13 from week 54 to 102 (8). In the PLANETAS extension study, the efficacy of CT-P13 in patients treated for 102 weeks was comparable with patients who changed from infliximab RP to CT-P13, and changing treatment had no adverse impact on safety or tolerability (8). The NOR-SWITCH trial, which included patients with

spondyloarthritis (SpA), as well as RA, PsA, chronic plaque psoriasis, Crohn's disease, and ulcerative colitis, investigated the efficacy and safety of changing from infliximab RP to CT-P13 with a 52-week follow-up (16). In this trial, drug discontinuation was similar between patients treated with infliximab RP and CT-P13 (16). A recent report of data from the DANBIO registry, which included patients with RA, PsA, and axial SpA, has shown that 1-year retention rates were similar between CT-P13 and infliximab RP (17). A real-world study, which included 109 patients with AS/SpA, found that 2-year drug retention rates were higher among patients receiving CT-P13 as their first infliximab product than in those receiving infliximab RP (18). A total of 30% and 62% of patients treated with CT-P13 or infliximab RP discontinued treatment within 2 years, respectively (18). Although such findings suggest that the efficacy and safety of CT-P13 are maintained during long-term treatment, they are limited by their relatively short follow-up duration.

The Korean College of Rheumatology Biologics (KOBIO) registry is a prospective, observational study established to gather and assess data on patients with RA, AS, and PsA who are receiving treatment with biologic therapies in Korea (19, 20). The original aims of this registry were to monitor the clinical course of the disease and safety issues emerging during treatment with biologic therapies (19); because data are collected during routine clinical practice, the registry provides a “real-world” perspective on these issues. The aim of this analysis from the KOBIO registry was to evaluate the long-term drug retention rate, retention time, efficacy, and safety of CT-P13 in Korean patients with AS who were followed for up to 4 years. In addition, we also investigated the outcomes between patients receiving CT-P13 as first-line or subsequent-line therapy.

## Methods

### Study population

The KOBIO registry (ClinicalTrials.gov identifier: NCT01965132) is an ongoing multicentre, prospective, obser-

*Funding: this study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).*

*Competing interests: Y.N. Lee and H.J. Kang are employees of Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). The other co-authors have declared no competing interests.*

ational study organised by the Korean College of Rheumatology (20, 21). The KOBIO registry includes information about patients with AS, PsA, or RA who are considered eligible for treatment with biologic therapies (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab) (21).

Patients are eligible for inclusion in the KOBIO registry if they are aged  $\geq 18$  years, and have a diagnosis of RA, AS, or PsA (21). The KOBIO registry enrolls patients with RA, AS, or PsA when the patient initiates or restarts a biologic therapy or when treatment is changed to another biologic agent (21). Patients previously treated with biologic therapies prior to screening may be included, but the efficacy outcome of this previous treatment is not recorded. We assessed data from patients with AS enrolled in the KOBIO registry between December 2012 and December 2017 who had received CT-P13, either as first-line treatment or following a change from another tumour necrosis factor (TNF) inhibitor. CT-P13 was approved by the Korean Ministry of Food and Drug Safety in July 2012 and was commercially available from September 2012. Non-medical switches were not included in this analysis. The present analysis was conducted according to the principles of the Declaration of Helsinki. Informed consent was obtained from all patients prior to the collection of any data, and the data collection form and study protocol were approved by institutional review boards or local ethics committees at each participating centre.

#### Data collection and outcomes

Data were collected annually from participating hospitals using standardised case report forms and uploaded by the investigators to the KOBIO web server. Baseline demographic data collected in the KOBIO registry included age, gender, body mass index, disease duration and activity, smoking status, human leucocyte antigen-B27 status, and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels. The following outcome measures were recorded for the assessment of disease activity at baseline: swollen joint count; tender

joint count; Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (22); Ankylosing Spondylitis Disease Activity Score (ASDAS) (23); and patient's global assessment (GA). The primary outcome of this analysis was drug retention (*i.e.* time to treatment discontinuation or changing to another biologic). Additional outcomes of this analysis included efficacy (disease activity) and safety. Efficacy was assessed by BASDAI; ASDAS-ESR, and ASDAS-CRP scores; and patient's GA. Safety was assessed by adverse events (AEs) categorised according to the Medical Dictionary for Regulatory Activities, version 17.0 (24).

Treatment-related data included details of treatment received (dates, and line of therapy), treatment changes and reasons for changing, and discontinuations and reasons for discontinuation. Discontinuation was defined as permanent discontinuation of biologic agents. Patients who did not have a documented time to discontinuation were included in the analyses of baseline demographics, efficacy, and safety, but were excluded from the analysis of drug retention rates.

#### Statistical analyses

The sample size was determined by the number of eligible Korean patients at participating centres during the study period. Drug retention was assessed by means of Kaplan-Meier curves. A log-rank test was performed to demonstrate differences in survival function. Confidence bands for the survival function were calculated using the method of Hall and Wellner (25). Secondary outcomes included clinically important improvements or major improvements in ASDAS scores. Clinically important improvement was defined as an improvement of at least 1.1 points between two consecutive values of ASDAS, and an improvement of at least 2 points was defined as a major improvement (26, 27). Descriptive statistics were derived for baseline levels and changes from baseline in BASDAI, ASDAS-ESR, ASDAS-CRP scores, and patient's GA. All statistical analyses were two-sided and were performed using SAS statistical software, v. 9.4 (SAS Institute), and

$p$ -values  $< 0.05$  were considered statistically significant.

## Results

### Patients

Between December 2012 and December 2017, 3,424 patients with AS ( $n=1,658$ ), RA ( $n=1,711$ ) and PsA ( $n=55$ ) were enrolled in the KOBIO registry; of these, 244 were patients with AS who were treated with CT-P13. These 244 patients comprised the analysis population reported here. The baseline demographic and clinical characteristics of these patients are summarised in Table I. The mean (standard deviation [SD]) age of patients was 38.8 (12.6) years and 73% of patients were male. All patients had active AS, as shown by baseline BASDAI, ASDAS-CRP, and ASDAS-ESR scores, with a mean (SD) disease duration of 4.2 (5.4) years.

At baseline, most patients (203/244; 83.2%) received CT-P13 as first-line therapy (Table I). Compared with patients treated with CT-P13 in the first-line setting, those receiving CT-P13 in second or subsequent lines had significantly longer disease duration (3.8 years vs. 6.1 years, respectively,  $p=0.010$ ) (Table I). However, there were no significant differences in BASDAI, ASDAS-CRP, or ASDAS-ESR scores between patients receiving CT-P13 as first-line or subsequent therapy (Table I).

### Treatment duration and drug retention

Data on treatment duration were available for 208 patients, of whom 173 were receiving CT-P13 as first-line therapy and 35 were receiving second-line or subsequent therapy. The overall median duration of CT-P13 treatment was 2.05 (range 0.04–4.18) years, and the median treatment durations in patients receiving first-line or subsequent CT-P13 therapy were 2.09 (range 0.04–4.18) and 1.11 (range 0.04–4.01) years, respectively. After up to 4 years' follow-up, the retention rate of CT-P13 was 66% in the overall patient population, and 67% in patients receiving CT-P13 as first-line therapy.

### Drug retention


Drug retention tended to be longer in patients receiving CT-P13 as first-line

**Table I.** Baseline demographic and clinical characteristics.\*

	CT-P13			p-value
	All patients (n=244)	1 <sup>st</sup> -line (n=203)	≥2 <sup>nd</sup> -line (n=41)	
Age, years	38.8 ± 12.6	38.7 ± 12.7	39.4 ± 12.4	0.754
Disease duration, years	4.2 ± 5.4	3.8 ± 5.3	6.1 ± 5.7	0.010
Male, n (%)	178 (73.0)	150 (73.9)	28 (68.3)	0.462
Smoking status, n (%)				0.653
Current smoker	65 (26.6)	52 (25.6)	13 (31.7)	–
Ex-smoker	51 (20.9)	42 (20.7)	9 (22.0)	–
Never	128 (52.5)	109 (53.7)	19 (46.3)	–
BMI, kg/m <sup>2</sup>	23.9 ± 3.2	24.1 ± 3.2	23.0 ± 3.2	0.043
Swollen joint count	0.8 ± 3.3	0.9 ± 3.5	0.6 ± 2.1	0.517
Tender joint count	1.4 ± 4.7	1.4 ± 4.7	1.3 ± 4.5	0.962
BASDAI score	6.3 ± 1.9	6.3 ± 1.9	6.4 ± 1.7	0.586
Patient's GA	6.4 ± 2.1	6.3 ± 2.2	6.6 ± 1.7	0.547
ASDAS-ESR	3.7 ± 1.0	3.7 ± 1.0	3.7 ± 1.0	0.89
ASDAS-CRP	3.7 ± 1.2	3.7 ± 1.3	3.5 ± 1.0	0.346
ESR, mm/h	35 ± 30.7	35 ± 30.5	35 ± 31.7	0.999
CRP, mg/dL	2.1 ± 2.9	2.1 ± 2.8	1.9 ± 3.5	0.742
HLA-B27 status, n (%)				0.700
Positive	192 (78.7)	158 (77.8)	34 (82.9)	–
Negative	33 (13.5)	28 (13.8)	5 (12.2)	–
Not determined	19 (7.8)	17 (8.4)	2 (4.9)	–

\*Data presented are mean ± standard deviation, unless otherwise indicated. p-value comparisons across biologic categories are based on the Chi-squared test of homogeneity for categorical variables; p-values for continuous variables are based on the t-test for the mean.

ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BMI: body mass index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; GA: global assessment; HLA-B27: human leukocyte antigen-B27.



**Fig. 1.** Kaplan-Meier plot of drug retention in patients with ankylosing spondylitis receiving CT-P13 as first-line or subsequent therapy for up to 4 years. Shaded area represents 95% Hall-Wellner bands, censored data are shown by +.

Drug retention estimates with number of subjects at risk and 95% Hall-Wellner bands. Events defined as CT-P13 discontinued or changed. 1L: first line; 2L: second line.

therapy than in those patients receiving it in subsequent lines from 4-year follow-up, but differences between groups were not statistically significant (log-rank  $p=0.2701$ ; Fig. 1).

*Therapy changes and discontinuations*

In the study population, 38/244 (15.6%) patients changed from CT-P13 to a different therapy, and 32 (13.1%) patients

discontinued CT-P13 without starting another biologic treatment (Table II). Rates of changing treatment and discontinuation were slightly higher in patients receiving CT-P13 as second-line or subsequent therapy than in those receiving as first-line therapy: 17.1% and 14.6%, respectively, in patients receiving second-line or subsequent treatment, compared with 15.3% and

12.8%, respectively, in those receiving first-line therapy (Table II). Overall, the most common reason for changing or discontinuing treatment was lack of efficacy (13.9% [34/244]). Lack of efficacy was the single most common reason for treatment changes. A total of five patients, all of whom were receiving CT-P13 as first-line therapy, discontinued therapy because clinical remission had been achieved.

AEs were the second most common reason for changing treatment or discontinuation, which occurred in 18/244 (7.4%) patients (Table II). AEs were the most common single cause of discontinuation. AEs leading to changing treatment or discontinuation of CT-P13 are listed in Supplementary Table SI. Overall, 10 patients (4.1%) changed from CT-P13 to another treatment because of AEs. The most common AEs resulting in treatment changes were infusion or injection-site reactions (n=8 events), skin rash (n=2 events), and uveitis (n=1 event) (Suppl. Table SI). Treatment discontinuations due to AEs occurred in 8 (3.3%) patients (Table II). The most common of these were infusion or injection-site reactions, *Mycobacterium tuberculosis* infection and headache (n=2 events each); conception, urticaria, and gastrointestinal disturbances each occurred once (Suppl. Table SI). Rates of changing treatment or discontinuation due to AEs were higher among patients receiving CT-P13 as second-line or subsequent therapy than in those receiving first-line therapy (Suppl. Table SI).

Details of the drugs received following CT-P13 are summarised in Table III. Following first-line CT-P13 treatment, the most commonly substituted drugs were golimumab (45.2%) or adalimumab (32.3%), followed by etanercept and infliximab RP; one patient (2.6%) was changed to an etanercept biosimilar (Table III). The same trend was seen in patients changing from second-line or subsequent CT-P13, in whom golimumab and adalimumab were the most commonly substituted products.

*Efficacy*

Median scores for BASDAI, ASDAS-ESR, ASDAS-CRP, and patient's GA are shown in Fig. 2. Disease activity as-

**Table II.** Reasons for discontinuing CT-P13 or changing from CT-P13 to another therapy.

	All patients (n=244)	1st-line treatment (n=203)	≥2nd-line treatment (n=41)
Changed, n (%) <sup>*</sup>	38 (15.6)	31 (15.3)	7 (17.1)
Lack of efficacy	27 (11.1)	23 (11.3)	4 (9.8)
AE	10 (4.1)	7 (3.4)	3 (7.3)
Unspecified	1 (0.4)	1 (0.5)	0
Discontinuation, n (%)	32 (13.1)	26 (12.8)	6 (14.6)
AE	8 (3.3)	6 (3.0)	2 (4.9)
Lack of efficacy	7 (2.9)	6 (3.0)	1 (2.4)
Clinical remission	5 (2.0)	5 (2.5)	0
Other	12 (4.9)	9 (4.4) <sup>†</sup>	3 (7.3) <sup>‡</sup>

<sup>\*</sup>Expressed as percentage of total number of patients.

<sup>†</sup>Reasons include lost to follow-up (n=4), patient's decision (n=2), optionally stopped (n=1), insurance costs (n=1), and unknown (n=1).

<sup>‡</sup>Reasons include patient's decision (n=2) and planning for pregnancy (n=1).

AE: adverse event.

**Table III.** Biologics received following change from CT-P13.

n (%)	All patients (n=38)	After 1st-line CT-P13 (n=31)	After ≥ 2nd-line CT-P13 (n=7)
Golimumab	17 (44.7)	14 (45.2)	3 (42.9)
Adalimumab	12 (31.6)	10 (32.3)	2 (28.6)
Etanercept	4 (10.5)	3 (9.7)	1 (14.3)
Infliximab <sup>*</sup>	4 (10.5)	3 (9.7)	1 (14.3)
Etanercept biosimilar	1 (2.6)	1 (3.2)	0

<sup>\*</sup>Infliximab reference product (Remicade<sup>®</sup>).

essed by BASDAI, ASDAS-ESR, ASDAS-CRP, and patient's GA, decreased markedly from baseline following initiation of CT-P13 treatment, and thereafter remained stable during follow-up (Fig. 2).

The proportion of patients showing clinically important or major changes in ASDAS scores (defined as ≥1.1 or ≥2-point improvements, respectively) are shown in Suppl. Table SII. In the overall patient population, 56.5% and 82.2% of patients showed a major or clinically important improvement in ASDAS score, respectively, after 1 year of treatment. These improvements were maintained at 2 years (major improvement: 56.9% of patients, clinically important improvement: 85.4% of patients) (Suppl. Table SII). Similarly, among patients receiving CT-P13 as first-line therapy, 59.9% experienced a major improvement in ASDAS score and 84.1% experienced a clinically important improvement at first follow-up, and similar proportions were seen at 2 years (54.7% and 85.8%, respectively).

### Safety

CT-P13 was well tolerated during long-

term treatment. Overall, 118 patients (48.4%) reported 313 AEs (Suppl. Table SIII), the majority of which were mild (grade 1) or moderate (grade 2) in severity (62.3% and 32.3%, respectively). A total of 72 AEs in 41 patients (16.8%) were considered by the investigators to be related to CT-P13 treatment (Suppl. Table SIII). Of these, the majority (63/72 events [87.5%]) of events occurred in patients receiving CT-P13 as first-line therapy. Treatment-related AEs occurring in two or more patients, and all grade 3 treatment-related AEs, are summarised in Table IV. The most common CT-P13-related AEs were infusion or injection-site reactions (4.1%), uveitis (3.7%), and skin rash (3.7%). A total of four grade 3 CT-P13-related AEs were reported: uveitis, infusion or injection-site reaction, *Mycobacterium tuberculosis* infection, and itching, which occurred in one patient each.


### Discussion

In this prospective, registry-based, observational study, CT-P13 demonstrated encouraging drug retention rates and retention times in Korean patients with

AS who were treated with CT-P13 as either first-line or subsequent therapy for a median of 2.05 years. Treatment discontinuations or changes were infrequent (13.1% and 15.6%, respectively); the majority of changes were due to a lack of efficacy (11.1%), whereas AEs were the most common single reason for discontinuation (3.3%).

Our analysis has demonstrated that CT-P13 had reasonable long-term efficacy and was well tolerated in this patient population. Disease activity was markedly improved at 1 year, compared with baseline, and these improvements were sustained over the 4-year follow-up period. Major improvements in ASDAS score were achieved in the majority of patients during the first year of treatment. The majority of AEs were mild or moderate in severity. The most common treatment-related AEs were infusion or injection-site reaction, uveitis, and skin rash, all of which occurred in fewer than 5% of patients.

Our findings with CT-P13 are consistent with previous studies of infliximab (28-32). In a Korean single-centre study involving patients with AS and RA, 79% of patients with AS treated with a first TNF inhibitor remained on treatment at 2 years; median drug retention time with infliximab RP did not differ from etanercept or adalimumab (30). Consistent with our study, AEs were the most common reason for discontinuation of TNF inhibitors in patients with AS, accounting for 39.7% of cases. A slightly higher discontinuation rate was reported in a single-centre study from Spain, in which 26.5% of patients with AS who received infliximab RP discontinued treatment during the 5-year follow-up period (29). In a Spanish single-centre study, the most common reason for discontinuation of TNF inhibitor therapy was lack of efficacy. Registry-based studies conducted in Spain (28) and the Czech Republic (32) have reported drug retention rates of approximately 72-76% after 3 years of follow-up in patients with AS receiving TNF inhibitors. A Swedish registry study demonstrated that comedication with conventional synthetic disease-modifying anti-rheumatic drugs was associated with TNF inhibitor drug



**Fig. 2.** Median scores for BASDAI (A), ASDAS-ESR (B), ASDAS-CRP (C), and patient’s global assessment (D) in the overall patient population, and in patients receiving first-line and second-line or subsequent CT-P13.

p-values were calculated using the Wilcoxon rank sum method comparing the medians of the first-line group and ≥ second-line group.

ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IQR: interquartile range.

retention in patients with AS (31). In these registry studies, the most common reasons for discontinuation of therapy were lack of efficacy (31) or AEs (28, 32). It is noteworthy that the single-centre and registry studies have consistently found that discontinuation rates of TNF inhibitor therapy are higher, and drug retention lower, in patients with RA, compared with AS or other forms of SpA (28, 30, 32).

As briefly mentioned, few studies to date have investigated the long-term drug retention, efficacy, or safety of

CT-P13 in patients with AS (8, 16, 33, 34). It is important to note that none of the previously reported studies followed patients for more than 2 years (8, 16, 18). As such, the 4-year follow-up in our analysis offers important insights into the efficacy and tolerability of CT-P13 during long-term treatment. In general, clinicians may have a number of key concerns about changing patients to a biosimilar, including potential loss of efficacy, changes in immunogenicity, and unanticipated differences in the safety profile com-

pared with the RP (35). These concerns may be addressed by the accumulating real-world experience with CT-P13 in routine clinical practice. Several recent studies have investigated the efficacy and safety of CT-P13 in patients with AS treated under “real-world” conditions, either as first-line infliximab therapy (36), or following a change from infliximab RP (37, 38). In a study from three European countries, which involved 70 patients with AS who were considered to be candidates for biologic therapy, 22 patients (31%) achieved

**Table IV.** CT-P13-related adverse events (occurring in  $\geq 2$  patients overall or  $\geq 1$  patient(s) at grade 3–4) in the overall patient population.

	n (%)	
	Grade 1–2	Grade 3
Eye disorder (NOS)	2 (0.8)	–
Uveitis	8 (3.3)	1 (0.4)
Gastrointestinal disorder (NOS)	3 (1.2)	–
Gastritis	2 (0.8)	–
General disorder (NOS)	5 (2.0)	–
Infusion/injection-site reaction	9 (3.7)	1 (0.4)
Mycobacteria tuberculosis infection	1 (0.4)	1 (0.4)
Transaminitis	3 (1.2)	–
Headache	2 (0.8)	–
Respiratory disorder (NOS)	2 (0.8)	–
Common cold*	5 (2.0)	–
Upper respiratory tract infection	3 (1.2)	–
Chronic urticaria	3 (1.2)	–
Itching	–	1 (0.4)
Skin rash	9 (3.7)	–

\*Recurrent in one patient.

NOS: not otherwise specified.

remission and 45 (64%) achieved low disease activity at the end of the 24-week treatment period with CT-P13 (36). A total of eight treatment-related AEs, the majority of which were mild or moderate in severity, were reported. Real-world studies in mixed populations of rheumatology patients have shown comparable efficacy and tolerability following a change from infliximab RP to CT-P13 (37, 38), and this experience is supported by studies in patients with IBD (39). It may be anticipated that, as real-world data continue to accrue, the cumulative evidence of the efficacy and safety of CT-P13 in patients with AS will allay concerns and aid clinical decision making.

In addition to offering efficacy and safety comparable with RPs, biosimilars may provide important economic benefits due to their lower cost, compared with the RP (12). While there are currently no cost-analyses specific to the use of CT-P13 in the treatment of patients with AS, several studies assessing the economic impact of changing from infliximab RP to CT-P13 in various indications provide compelling evidence of the cost saving of CT-P13 (40–43). For example, a budget impact analysis investigating the potential savings over 1 year following the introduction of CT-P13 for various indications in five European countries found that annual cost savings ranged from €2.89 million in Belgium to

€33.8 million in Germany, depending on the level of discount applied (42). Across the five countries, the cumulative savings in drug costs ranged from €25.79 million to €77.37 million. The modeled population included both infliximab-naïve patients and patients who changed from infliximab RP to CT-P13. Cost savings achieved with CT-P13 may enable more patients to be treated (40, 44, 45). In countries where infliximab is not recommended due to cost constraints, introduction of the lower-priced CT-P13 might alter this situation.

A key strength of this study is that it provides real-world data from Korean patients with AS who are receiving treatment with biologic therapies. Additional strengths of this study include the long duration of follow-up, the prospective nature of the KOBIO registry, and the relatively large patient population studied. Potential limitations include the relatively small number of patients receiving CT-P13 as second-line or subsequent therapy, and the possibility of bias since the registry includes only patients treated at participating centres. Moreover, as the median treatment duration of CT-P13 was 2.05 years and only 12 of 208 patients received treatment for 4 years, rare AEs such as malignancy may not be observed. This limitation may be overcome with longer follow-up or recruitment of additional patients. A further

potential limitation is that the study did not investigate efficacy outcomes in patients who changed from infliximab RP to CT-P13, or vice versa.

In conclusion, CT-P13 demonstrated encouraging drug retention rates and retention times, as well as reasonable long-term efficacy and safety, in Korean patients with AS.

### Acknowledgements

Medical writing support (including development of a draft outline and subsequent drafts in consultation with the authors, assembling tables and figures, collating author comments, copyediting, fact checking and referencing) was provided by Emma Evans, PhD, CMPP, at Aspire Scientific (Bollington, UK), and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).

### References

- SCHULZE-KOOPS H, SKAPENKO A: Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. *Rheumatology* (Oxford) 2017; 56: iv30–48.
- EUROPEAN MEDICINES AGENCY: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014; Available at: [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active\\_en-2.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf). Accessed 1 July 2019.
- US FOOD & DRUG ADMINISTRATION: What is a biosimilar? 2018; Available at: <https://www.fda.gov/media/108905/download>. Accessed 1 July 2019.
- WORLD HEALTH ORGANIZATION: Norms and standards. WHO Drug Information 2015; 29: 138–41.
- MCKEAGE K: A review of CT-P13: an infliximab biosimilar. *BioDrugs* 2014; 28: 313–21.
- PARK W, HRYCAJ P, JEKA S *et al.*: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Ann Rheum Dis* 2013; 72: 1605–12.
- YOO DH, HRYCAJ P, MIRANDA P *et al.*: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Ann Rheum Dis* 2013; 72: 1613–20.
- PARK W, YOO DH, MIRANDA P *et al.*: Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS exten-

- sion study. *Ann Rheum Dis* 2017; 76: 346-54.
9. YOO DH, PRODANOVIC N, JAWORSKI J *et al.*: Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. *Ann Rheum Dis* 2017; 76: 355-63.
  10. US FOOD & DRUG ADMINISTRATION: INFLECTRA (infliximab-dyyb) prescribing information. 2016; Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/125544s0001bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s0001bl.pdf) Accessed 1 July 2019.
  11. GABBANI T, DEIANA S, ANNESE V: CT-P13: design, development, and place in therapy. *Drug Des Devel Ther* 2017; 11: 1653-61.
  12. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH: Switching from innovator to biosimilar (subsequent entry) infliximab: a review of the clinical effectiveness, cost-effectiveness, and guidelines. 2015; Available at: <https://www.cadth.ca/media/pdf/htis/mar-2015/RC0635%20Infliximab%20Switching%20Final.pdf>. Accessed 1 July 2019.
  13. EUROPEAN MEDICINES AGENCY: European Public Assessment Report: Remsima. 2018; Available at: [https://www.ema.europa.eu/en/documents/product-information/remsimapar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/remsimapar-product-information_en.pdf). Accessed 24 August 2018.
  14. PARK W, YOO DH, JAWORSKI J *et al.*: Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Res Ther* 2016; 18: 25.
  15. BAJI P, PENTEK M, SZANTO S *et al.*: Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. *Eur J Health Econ* 2014; 15 (Suppl. 1): S45-52.
  16. JORGENSEN KK, OLSEN IC, GOLL GL *et al.*: Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. *Lancet* 2017; 389: 2304-16.
  17. GLINTBORG B, SORENSEN UJ, LOFT AG *et al.*: A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. *Ann Rheum Dis* 2017; 76: 1426-31.
  18. NIKIPHOROU E, HANNONEN P, ASIKAINEN J *et al.*: Survival and safety of infliximab biooriginal and infliximab biosimilar (CT-P13) in usual rheumatology care. *Clin Exp Rheumatol* 2019; 37: 55-9.
  19. KIM SK, CHOE JY, LEE SS, SHIN K: Body mass index is related with the presence of syndesmophyte in axial spondyloarthritis: Data from the Korean College of Rheumatology BIOlogics (KOBIO) registry. *Mod Rheumatol* 2017; 27: 855-61.
  20. PARK DJ, CHOI SJ, SHIN K *et al.*: Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. *Clin Rheumatol* 2017; 36: 1013-22.
  21. SHIN K: Korean College of Rheumatology Biologics Registry (KOBIO). Available at: <https://clinicaltrials.gov/ct2/show/NCT01965132>. Accessed 1 July 2019.
  22. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 1994; 21: 2286-91.
  23. LUKAS C, LANDEWÉ R, SIEPER J *et al.*: Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009; 68: 18-24.
  24. MedDRA. Medical Dictionary for Regulatory Affairs. 2018; Available at: <https://www.meddra.org/>. Accessed 1 July 2019.
  25. HALL WJ, WELLNER JA: Confidence bands for a survival curve from censored data. *Biometrika* 1980; 67: 133-43.
  26. MACHADO P, LANDEWE R, LIE E *et al.*: Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. *Ann Rheum Dis* 2011; 70: 47-53.
  27. MACHADO PM, LANDEWÉ RB, VAN DER HEIJDE DM: Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. *J Rheumatol* 2011; 38: 1502-6.
  28. CARMONA L, GÓMEZ-REINO JJ: Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. *Arthritis Res Ther* 2006; 8: R72.
  29. GARCÍA-LAGUNAR MH, GUTIÉRREZ-CÍVICOS MR, GARCÍA-SIMÓN MS *et al.*: Reasons for discontinuation and adverse effects of TNF- $\alpha$  inhibitors in a cohort of patients with rheumatoid arthritis and ankylosing spondylitis. *Ann Pharmacother* 2017; 51: 388-93.
  30. KANG JH, PARK DJ, LEE JW *et al.*: Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. *J Korean Med Sci* 2014; 29: 1205-11.
  31. LIE E, KRISTENSEN LE, FORSBLAD-D'ELIA H, ZVERKOVA-SANDSTROM T, ASKLING J, JACOBSSON LT: The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. *Ann Rheum Dis* 2015; 74: 970-8.
  32. PAVELKA K, FOREJTOVA S, STOLFA J *et al.*: Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. *Clin Exp Rheumatol* 2009; 27: 958-63.
  33. HOLROYD CR, PARKER L, BENNETT S *et al.*: Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis. *Clin Exp Rheumatol* 2018; 36: 171-2.
  34. NIKIPHOROU E, HANNONEN P, ASIKAINEN J *et al.*: Survival and safety of infliximab biooriginal and infliximab biosimilar (CT-P13) in usual rheumatology care. *Clin Exp Rheumatol* 2019; 37: 55-9.
  35. AZEVEDO V, DÖRNER T, STROHAL R *et al.*: Biosimilars: considerations for clinical practice. *Considerations Med* 2017; 1: 13-8.
  36. CODREANU C, SIROVA K, JAROSOVA K, BATALOV A: Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. *Curr Med Res Opin* 2018; 34: 1763-9.
  37. BENUCCI M, GOBBI FL, BANDINELLI F *et al.*: Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. *Immunol Res* 2017; 65: 419-22.
  38. MALAIYA R, MCKEE Z, KIELY P: Infliximab biosimilars – switching Remicade to Remsima in routine care: patient acceptability and early outcome data. *Rheumatology* 2016; 55: i125-6.
  39. MOOTS R, AZEVEDO V, COINDREAU JL *et al.*: Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. *Curr Rheumatol Rep* 2017; 19: 37.
  40. BRODSZKY V, BAJI P, BALOGH O, PENTEK M: Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. *Eur J Health Econ* 2014; 15 (Suppl. 1): S65-71.
  41. GIBOFSKY A, SKUP M, YANG M, MITTAL M, MACAULAY D, GANGULIA A: Short-term costs associated with non-medical switching in autoimmune conditions. *Clin Exp Rheumatol* 2019; 37: 97-105.
  42. JHAA A, UPTON A, DUNLOP WC, AKEHURST R: The budget impact of biosimilar infliximab (Remsima) for the treatment of autoimmune diseases in five European countries. *Adv Ther* 2015; 32: 742-56.
  43. MCCARTHY G, EBEL BITOUN C, GUY H: Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. *Value Health* 2013; 16: A558.
  44. BRAUN J, KUDRIN A: Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. *Biologicals* 2016; 44: 257-66.
  45. GULACSI L, BRODSZKY V, BAJI P *et al.*: Biosimilars for the management of rheumatoid arthritis: economic considerations. *Expert Rev Clin Immunol* 2015; 11 (Suppl. 1): S43-52.